ARCHIVES

Groups Lobby Congress For $5.8 Billion Budget For NCI, Increases For Other Programs

This article is from The Cancer Letter archive.

Vol. 36 No. 23 | June 18, 2010

Download PDF Visit The Full Archive

Related Articles

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

May 7, 2004

Letter: Headline Criticized On Letter About Consortium

June 21, 1996

CMS Launches National Coverage Analysis, Citing FDA’s Black Box Warning on ESAs.

March 16, 2007

ACLU Sues Myriad, U.S. Patent Office Over Patents For BRCA Gene Mutations

May 15, 2009

FDA Advisors: DepoCyt May Test Accelerated Approval Mechanism

November 27, 1998

FDA Says Medicare Policy On ESAs “Consistent With The Available Data.”

October 19, 2007